Casandra
Casandra Test Code QD86849Version 1 (DRAFT)
Performing Lab
CEBPA Mutation Analysis
Clinical Use
Order TestUse
The CEBPA gene, a myeloid transcription factor, is mutated in a subset of acute myeloid leukemia (AML), particularly those with cytogenetically normal (diploid) karyotypes. Patients with CN‑AML harboring CEBPA mutations demonstrate a favorable prognosis relative to other CN‑AML groups. Testing for CEBPA mutations, alongside NPM1 mutation analysis, is recommended for all patients with cytogenetically normal AML.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
NGS
Biomarkers
CEBPA
GeneSNV/Indel
Mutation • Categorical (e.g., Positive / Negative / Indeterminate)
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
2 mL
Container
EDTA (lavender‑top) tube
Causes for Rejection
Gross hemolysis • Received frozen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 7 days |
| Refrigerated | 7 days |
Similar Tests
Other tests from different labs that may be relevant
CEBPA Mutation Analysis
Labcorp
CEBPA Mutation Analysis
NeoGenomics
Acute Myeloid Leukemia Mutation Panel by Next Generation Sequencing
ARUP Laboratories
NPM1 Mutation Analysis
Labcorp
NPM1 Mutation Analysis
NeoGenomics
Rapid Acute Myeloid Leukemia Targeted Therapy Mutation Panel
ARUP Laboratories
NPM1 Mutation Detection by RT-PCR, Quantitative
ARUP Laboratories
Nucleophosmin (NPM1) Mutation Analysis, Varies
Mayo Clinic Lab
Myeloid Malignancies Mutation and Copy Number Variation Panel by Next Generation Sequencing
ARUP Laboratories
NPM1 MRD Analysis
NeoGenomics